Tag: payloads
20-Hour Conjugation Bottlenecks – Confronting ADC Development Challenges with CDMOs
20-Hour Conjugation Bottlenecks – Confronting ADC Development Challenges with CDMOs
Developing ‘Next-Gen’ Therapeutics: a First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC
Bispecific ADCs (bsADCs) are positioned as an emerging, next-generation, class of therapeutics, combining the dual-targeting capabilities of bispecific antibodies (bsAbs) with the potent cytotoxicity of antibody-drug conjugates (ADCs). The resulting bsADC offers improved efficacy and safety for the treatment of heterogeneous solid tumors.
Simris and Lonza Sign Partnership Agreement to Promote Novel Payload Technology
Sweden-based Simris Group, a European biologics company focused on extracting high value biological active compounds from microalgae and cyanobacteria, has signed a strategic collaboration...
Advancements in the Development of ADC-technology for Cancer Treatment
In an article published in Future Drug Discovery, Justyna Mysliwy, Bioconjugation Team Leader at Iksuda Therapeutics, writes about the de developments in the technology...
Denintuzumab Mafodotin: Testing Novel Regimens for Frontline and Relapsed DLBCL
Highlighted clinical data with denintuzumab mafodotin (SGN-CD19A; 19A; Seattle Genetics) in B-cell malignancies, including diffuse large B-cell lymphoma, also known as DLBCL, and B-lineage...
Q&A – an Interview with Lonza’s Laurent Ducry
Antibody-drug Conjugates or ADCs are among the most exciting drug developments of the last decade. The combination of potent, small molecule drugs with the...
A Chemistry Driven Approach to Uniform Antibody-drug Conjugates: New Data on...
Earlier today, during a plenary session of the 2015 World ADC Summit, being held October 26-29, 2014 in San Diego, California, Randall Halcomb, PhD, Vice President Chemistry at Igenica Biotherapeutics,
presented new data utilizing the company's SNAP site-specific ADC linker technology.
